Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer

Urology

Volumn 61, Issue 5, 2003, Pages 993-998

  Noguchi, Masanori ^a   Yahara, Jyunro ^a   Noda, Shinshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; COLLAGEN TYPE 1; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; LEUPRORELIN; MARKER; PEPTIDE; PROCOLLAGEN C PROTEINASE; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CROSS LINKING; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 0037963946     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02583-9     Document Type: Article

References (26)

1. Figg W.D., Ammerman K., Patronas N., et al. Lack of correlation between prostate specific antigen and presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. 14:1996;513-516.
2. 99mTc-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases. Clin Radiol. 28:1977;107-117.
3. Smith P.H., Bono A., Calais da Silva F., et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer a subanalysis of EORTC trial 30853 . Cancer. 66:1990;1009-1016.
4. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 17:1999;948-957.
5. Melkko J., Niemi S., Risteli L., et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 36:1990;1328-1332.
6. Francini G., Gonnelli S., Petrioli R., et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev. 2:1993;125-129.
7. Risteli J., Elomana I., Niemi S., et al. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen a new serum marker of bone collagen degradation . Clin Chem. 39:1993;635-640.
8. Kylmälä T., Tammela T.L.J., Risteli L., et al. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 71:1995;1061-1064.
9. Nakashima J., Sumitomo M., Miyajima A., et al. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol. 157:1997;1736-1739.
10. Akimoto S., Furuya Y., Akakura K., et al. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis comparison with the extent of disease (EOD) grade . Prostate. 38:1999;28-34.
11. Koga H., Naito S., Koto S., et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate. 39:1999;1-7.
12. Noguchi M., Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol. 166:2001;1106-1110.
13. Urwin G.H., Percival R.C., Harris S., et al. Generalized increase in bone resorption in carcinoma of the prostate. Br J Urol. 57:1985;721-723.
14. Charhon S.A., Chapuy M.C., Delvin E.E., et al. Histomorphometric analysis of sclerotic bone metastases from prostate carcinoma with special reference to osteomalacia. Cancer. 51:1983;918-924.
15. Clarke N.V., McClure J., George J.R. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 69:1992;64-70.
16. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 61:1988;195-202.
17. Noguchi M., Kikuchi H., Ishibashi M., et al. Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer. 88:2003;195-201.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216.
19. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendation from the Prostate-Specific Antigen Working Group . J Clin Oncol. 17:1999;3461-3467.
20. Tarle M., Kovacic K., Strelkov-Alfirvic A. Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostate acid phosphatase in monitoring patients with disseminated cancer of prostate. Prostate. 15:1989;211-219.
21. Cooper E.H., Whelan P., Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate. 25:1994;236-242.
22. Lorente J.A., Morote J., Raventos C., et al. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol. 155:1996;1348-1351.
23. Koizumi M., Yonese J., Fukui I., et al. Serum PINP level is a sensitive marker of prostate cancer metastasis to bone. BJU Int. 87:2001;348-351.
24. Koizumi M., Yonese J., Fukui I., et al. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol. 167:2002;1863-1866.
25. Rifas L., Kenney J.S., Pacifici R., et al. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells evidence that induction by interleukin-1 and tumor necrosis factor-α is not regulated by ovarian steroids . Endocrinology. 136:1995;4056-4067.
26. Noldus J., Stamey T.A. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficient. J Urol. 155:1996;232-237.